ArticleBJU international2026
Staging metastatic urothelial cancer with Nectin-4 imaging using Gallium-68-N188 PET/CT.
Article in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Predicting Therapeutic Response to Antibody-Drug Conjugates Using Targeted PET Imaging: A Systematic Review.Cancers · 2026Review
- [Innovative imaging techniques for urothelial carcinoma].Urologie (Heidelberg, Germany) · 2026Review
- "Precision on Two Wheels"─Structural Refinement ofJournal of medicinal chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo quantify Nectin-4 expression in tumour lesions using the Nectin-4-binding peptide Gallium-68-N188 and positron emission tomography (PET)/computed tomography (CT) in patients with advanced or metastasised urothelial cancer eligible for therapy with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin, in combination with checkpoint inhibitor pembrolizumab (Ev/P).
methodsIn 10 patients, Nectin-4 PET/CT imaging was analysed before planned systemic therapy with Ev/P based on standardised uptake value (SUV) measurements and the results were correlated to available microscopic findings on Nectin-4 immunohistochemistry and to clinical follow-up.
resultsNectin-4 PET is suitable for detecting Nectin-4 expression in tumour lesions and demonstrates heterogeneity in Nectin-4 expression - for example, between lymph node metastases and organ metastases. PET imaging of Nectin-4 expression is therefore a potentially clinically relevant method for managing the application of Nectin-4-targeted therapies.
conclusionsWe show, as a proof of principle, that Nectin-4 expression can be detected on imaging and serves as an innovative biomarker for targeted therapy in urothelial cancer. Intra-individual heterogeneous expression of Nectin-4 in metastatic sites is frequent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.